Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

By Köstler Wolfgang J.   Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 73-84

Springer Publishing Company

Access to resources Recommend Favorite

Taxane chemotherapy treatment for metastatic breast cancer

By Makower Della   Bachegowda Lohith S   Sparano Joseph A  

Breast Cancer Management, Vol. 2, Iss. 6, 2013-11 ,pp. : 507-517

Future Medicine

Access to resources Recommend Favorite

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

By Wildiers H.  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 463-469

Springer Publishing Company

Access to resources Recommend Favorite

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy

By Kim Ji-Won   Kim Jee   Im Seock-Ah   Lee Kyung-Hun   Kim Jin-Soo   Kim Tae-Yong   Han Sae-Won   Jeon Yoon   Oh Do-Youn   Kim Tae-You   Park In  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1023-1029

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

By Di Leo A.  

Breast Cancer Research and Treatment, Vol. 86, Iss. 3, 2004-08 ,pp. : 197-206

Springer Publishing Company

Access to resources Recommend Favorite